<DOC>
	<DOCNO>NCT02309450</DOCNO>
	<brief_summary>ANRS HC 33 pilot study assess efficacy safety DCV 3DAA therapy Asunaprevir , Daclatasvir BMS-791325 HCV genotype 4-infected patient failure pegylated Interferon-Ribavirin regimen . Proportion patient cirrhosis limit 50 % patient include , cirrhosis define METAVIR score F4 liver biopsy hepatic impulse elastometry ≥ 14 kPa Fibrotest® result &gt; 0,75 .</brief_summary>
	<brief_title>Pilot Study Assess Efficacy Safety Triple Therapy With Asunaprevir , Daclatasvir , BMS-791325 HCV Genotype 4-infected Patients After Failure Pegylated Interferon-Ribavirin Regimen</brief_title>
	<detailed_description>The clinical trial multi-centre , national , Phase 2 , open-label , single-arm . The primary objective study ass , HCV genotype 4-infected patient failure prior treatment pegylated Interferon Ribavirin bitherapy , rate sustain virological response ( SVR ) 12 week 12 week treatment all-oral combination 3 DAAs Fixed-Dose-Combination ( Asunaprevir 200 mg , Daclatasvir 30 mg BMS - 791325 75 mg ) twice day . Estimated enrollment 60 patient enrolment period ( 9 month ) . Schedule assessment : w4-w8 : screening D0 : Start anti-HCV tritherapy ( Asunaprevir + Daclatasvir + BMS-791325 ) w12 : stop tritherapy w24 : Sustained virological response SVR12 assessment ( 12 week post treatment ) w36 : Sustained virological response SVR24 assessment ( 24 week post treatment )</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Adult ≥18 year Infection HCV genotype 4 , confirm detectable HCV RNA ≥ 1000 IU/ml preinclusion Failure prior treatment pegylated Interferon Ribavirin , failure define follow : Nonresponse : HCV viral load remain detectable end P/R treatment . Relapse : undetectable HCV viral load P/R treatment detectable end treatment . HCV breakthrough : undetectable HCV viral load P/R treatment become detectable end treatment . AntiHCV treatment discontinue least last 3 month Fibrosis stage , documentation presence absence cirrhosis preinclusion visit : history liver biopsy show cirrhosis lesion ( METAVIR F4 ) , time patient 's history , good quality ( length ≥ 1 cm ≥ 5 portal space ) liver biopsy date less 18 month establish METAVIR , hepatic impulse elastometry ( Fibroscan® ) date less 6 month good quality ( least 10 measurement incidence IQR le 30 % median elastometry measure success rate 60 % ) interpretable Fibrotest® date less 6 month The proportion patient cirrhosis limit 50 % patient include , cirrhosis define METAVIR score F4 liver biopsy hepatic impulse elastometry ≥ 14 kPa Fibrotest® result &gt; 0,75 . Men woman childbearing age heterosexual partner must use adequate contraception treatment 8 week end treatment woman , 12 week end treatment men . Written inform consent sign patient investigator ( day preinclusion late examination require study ) ( article L112211 Public Health Code ) Patients Health insurance ( Sécurité Sociale Couverture Médicale Universelle ) Medical history CHILD B C cirrhosis Previous HCV therapy include HCV NS3 protease inhibitor , and/or HCV NS5A replication complex inhibitor and/or HCV NS5B polymerase inhibitor Current condition Positive HBs Antigen Confirmed HIV1 HIV2 infection Pregnant breastfeed woman Transplant recipients Any evolutive ongoing malignant disease , include hepatocellular carcinoma , specifically screen inclusion Consumption alcohol , investigator 's opinion , obstacle patient 's participation his/her remain study Drug addiction , investigator 's opinion , obstacle patient 's participation his/her remain study . Patients include programme substitution methadone buprenorphine could include . The opinion addictology consultant recommend patient present current drug use drug use past year . Patients take part another clinical trial 30 day prior inclusion Patient guardianship , trusteeship judicial protection Biological criterion ALT ≥ 5xULN Total bilirubin ≥ 34 µmol/L , unless document history Gilbert 's disease Hb &lt; 85 g/L Platelets &lt; 50 000/mm3 Kidney failure define creatinine clearance &lt; 50mL/mn ( MDRD formula ) QTc &gt; 440 msec male 460 msec female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>